Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis

Correction to: Leukemia ; https://doi.org/10.1038/leu.2017.112; published online 3 April 2017

Owing to the insufficient specificity of the anti-myeloproliferative leukemia protein (MPL) antibody in the original version of this Article, Figure 6 and parts of Figures 2a, 4e, and 5a do not represent the correct information. The corrected version of Figure 6 is in this correction and those of Figures 2a, 4e, and 5a are shown in the supplemental information.

Fig. 6

The number of SLAMF7^high CD16^high monocytes in human peripheral blood mononuclear cells (PBMCs) were increased in secondary myelofibrosis (MF) patients. a Representative flow cytometry histogram showing the expression of SLAMF7 in the mouse fibrocyte cell line and human cultured fibrocytes. Data are representative of five fibrocyte cell lines and three human cultured fibrocytes. b Approximately 7% of human CD45⁺ CD14⁺ monocytes expressed SLAMF7^high CD16^high. Data are representative of five human PBMCs from healthy donors. c The ratio of spindle-shaped cells in human purified SLAMF7^high CD16^high monocytes and SLAMF7^low CD16^low monocytes cultured with romiplostim (Rom). A significantly higher frequency of fibrocytes were differentiated from SLAMF7^high CD16^high monocytes (unpaired t-test, P < 0.01). d PBMCs of MF patients not treated with ruxolitinib (Rux) contained a significantly higher number of SLAMF7^high CD16^high monocytes than those of healthy donors and MF patients treated with Rux (one-way ANOVA with a Bonferroni correction, P < 0.01). The bar indicates the mean